

CRISPR-Cas

Adapting to change

Jackson, Simon A.; McKenzie, Rebecca E.; Fagerlund, Robert D.; Kieper, Sebastian N.; Fineran, Peter C.; Brouns, Stan J.J.

DOI

[10.1126/science.aal5056](https://doi.org/10.1126/science.aal5056)

Publication date

2017

Document Version

Accepted author manuscript

Published in

Science

Citation (APA)

Jackson, S. A., McKenzie, R. E., Fagerlund, R. D., Kieper, S. N., Fineran, P. C., & Brouns, S. J. J. (2017). CRISPR-Cas: Adapting to change. *Science*, 356(6333), 1-9. Article eaal5056. <https://doi.org/10.1126/science.aal5056>

Important note

To cite this publication, please use the final published version (if applicable). Please check the document version above.

Copyright

Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.

Takedown policy

Please contact us and provide details if you believe this document breaches copyrights. We will remove access to the work immediately and investigate your claim.

1 **Title:**

2 **CRISPR-Cas: adapting to change**

3

4 **Authors:**

5 Simon A. Jackson^{1†}, Rebecca E. McKenzie^{2†}, Robert D. Fagerlund¹, Sebastian N. Kieper², Peter
6 C. Fineran^{1,3*} and Stan J.J. Brouns^{2,4*}

7

8 **Affiliations:**

9 ¹Department of Microbiology and Immunology, University of Otago, PO Box 56, Dunedin 9054,
10 New Zealand.

11 ²Department of Bionanoscience, Kavli Institute of Nanoscience, Delft University of Technology,
12 Van der Maasweg 9, 2629 HZ Delft, The Netherlands.

13 ³Bio-Protection Research Centre, University of Otago, PO Box 56, Dunedin 9054, New Zealand.

14 ⁴Laboratory of Microbiology, Wageningen University, The Netherlands.

15

16 †These authors contributed equally

17 *Co-corresponding authors. E-mail. peter.fineran@otago.ac.nz; Tel. +64 (0)3 479 7735; Fax. +64
18 (0)3 479 8540 or Email. stanbrouns@gmail.com; Tel: +31-15 278 3920

19

20 **Abstract:**

21 Bacteria and archaea are engaged in a constant arms race to defend against the ever-present threats
22 of viruses and invasion by mobile genetic elements. The most flexible weapons in the prokaryotic
23 defense arsenal are the CRISPR-Cas adaptive immune systems, which are capable of selective
24 identification and neutralization of foreign elements. CRISPR-Cas systems rely on stored genetic
25 memories to facilitate target recognition. Thus, to keep pace with a changing pool of hostile
26 invaders, the CRISPR memory banks must be regularly updated by the addition of new
27 information, through a process termed adaptation. In this review, we outline the recent advances
28 in our understanding of the molecular mechanisms governing adaptation and highlight the
29 diversity between systems.

30

31 **One Sentence Summary:**

32 How prokaryotes adapt their CRISPR memory to constantly-evolving invaders

33

34 **Main Text:**

35


36 *Adaptive immunity in prokaryotes*

37 Bacteria and archaea are constantly threatened by phage infection and invasion by mobile genetic
38 elements (MGEs) through conjugation and transformation. In response, a defense arsenal has
39 evolved, including various ‘innate’ mechanisms and the CRISPR-Cas adaptive immune systems
40 (1-3). CRISPR-Cas systems are widely distributed, present in 50% and 87% of complete bacterial
41 and archaeal genomes, respectively, and are classified into two major classes consisting of 6 types
42 according to their Cas proteins (4, 5). CRISPR-Cas systems function as RNA-guided nucleases
43 that provide sequence-specific defense against invading MGEs (6, 7). Their repurposing,
44 particularly Cas9, has stimulated a biotechnological revolution in genome editing that has resulted
45 in breakthroughs across many biological fields (8). In native hosts, the advantage conferred by
46 CRISPR-Cas systems over innate defenses lies in the ability to update their resistance repertoire
47 in response to infection (termed CRISPR adaptation). Adaptation is achieved by incorporating
48 short DNA fragments from MGEs into CRISPR arrays to form memory units termed spacers,
49 which are subsequently transcribed and processed to CRISPR RNAs (crRNAs) (**Fig. 1**). Cas
50 proteins associate with crRNAs to form crRNA-effector complexes, which seek and destroy
51 invading MGEs. Thus, adaptation of CRISPR arrays is a crucial process required to ensure
52 persistent CRISPR-Cas defense (9, 10).

53 Adaptation in nature appears widespread, highlighting the dynamic interaction between hosts and
54 invaders (11-13). When a prokaryotic community undergoes CRISPR adaptation, individual cells
55 acquire different, and often multiple spacers. This population diversity increases defense by
56 limiting the reproductive success of MGE variants that evade recognition through genetic
57 mutations (escape mutants) (14). The CRISPR polymorphisms resulting from adaptation enable
58 differentiation of species subtypes, including economically and clinically relevant isolates, and
59 allow tracking of pathogen outbreaks (15, 16).

60 Typically, new spacers are inserted at one end of the array in a position closest to the promoter
61 driving CRISPR transcription – termed the leader (**Fig. 1**) (6, 17-19). This polarization of the
62 CRISPR records provides a chronological account of the battle between phages and bacteria,
63 analyses of which can provide insights into phage-host co-occurrences, evolution and ecology (20,
64 21). Moreover, spacer integration at the leader end enhances defense against recently encountered
65 MGEs, potentially due to elevated crRNA abundance (22). However, in some systems, the repeats
66 themselves contain internal promoters, which might make leader-proximal spacer integration less
67 important (23). CRISPR arrays typically contain 10-30 spacers, but some species contain arrays
68 with over 500 spacers (24). Spacers that may no longer be under evolutionary selection can be lost
69 via recombination between CRISPR repeats (11, 25).

70



71

72 **Fig. 1: CRISPR-Cas adaptation and defense.** A simplified schematic of CRISPR-Cas defense,
 73 which consists of an array of Clustered Regularly Interspaced Short Palindromic Repeats
 74 (CRISPR) and CRISPR-associated (Cas) proteins encoded by *cas* genes (omitted for clarity).
 75 CRISPR-Cas defense consists of three defined stages 1) Adaptation, the creation of memory of
 76 prior infections formed via the insertion of small foreign DNA sequences into the leader (L) end
 77 of the CRISPR array, where they are stored as spacers (colored squares) between duplicated
 78 repeats (R). 2) Expression and CRISPR-RNA (crRNA) biogenesis, the transcription and
 79 processing of the array into small guide RNA sequences. 3) Interference, degradation of the target
 80 foreign invader by sequence-specific binding and cleavage.

81

82 Early bioinformatic studies showed many spacers were of foreign origin, hinting that CRISPR loci
 83 would form the memory of an immune system (15, 26-28). Subsequent confirmation of this link
 84 between spacers and resistance to phage and MGEs was gained experimentally (6, 7, 29). Despite
 85 the elegance of memory-directed defense, CRISPR adaptation is not without complications.
 86 Paradoxically, the spacers required for defense must be added to CRISPRs during exposure to
 87 MGEs (30, 31). In addition, the inadvertent acquisition of spacers from host DNA must be avoided
 88 because this will result in cytotoxic self-targeting – akin to autoimmunity (32, 33). Recently,
 89 significant progress has been made toward understanding the molecular mechanisms governing
 90 how, when and why CRISPR spacers are acquired. Here, we review these studies and highlight
 91 the insights they shed on both the function and evolution of CRISPR-Cas systems.

92

93 ***Molecular mechanism of adaptation***

94 At the forefront of adaptation are Cas1 and Cas2 proteins, which form a Cas1₄-Cas2₂ complex (34,
 95 35) (hereafter Cas1-Cas2) – the ‘workhorse’ of spacer integration (Fig. 2). Illustrative of their key
 96 roles in spacer integration, the *cas1* and *cas2* genes are associated with nearly all CRISPR-Cas
 97 systems (4). Cas1-Cas2-mediated spacer integration prefers dsDNA substrates and proceeds via a

98 mechanism resembling retroviral integration (36, 37). In addition to Cas1-Cas2, a single repeat, at
99 least part of the leader sequence (17, 18, 22, 38), and additional host factors for repair of the
100 insertion sites (e.g. DNA polymerase) are required (39). Spacer integration requires three main
101 processes: 1) substrate capture 2) recognition of the CRISPR locus and 3) integration within the
102 array.

103

104 *Substrate capture*

105 During substrate capture, Cas1-Cas2 is loaded with an integration-compatible pre-spacer, which
106 is thought to be partially duplexed DNA. In the Cas1-Cas2:pre-spacer complex, each single-
107 stranded 3'OH end of the pre-spacer DNA extends into a single active subunit of each Cas1 dimer
108 (40) located either side of a central Cas2 dimer (41, 42) (Fig. 2). The branch points of the splayed
109 DNA are stabilized by a Cas1 wedge, which acts as a molecular ruler to control spacer length.
110 Although it is likely that Cas1-Cas2 rulers exist and measure different spacer sizes in all systems,
111 the mechanism has only been demonstrated in the *Escherichia coli* type I-E system, where two
112 tyrosine residues bookend the core 23 nt dsDNA region (41, 42). Details of how pre-spacer
113 substrates are produced from foreign DNA is discussed later.


114

115 *Recognition of the CRISPR locus*

116 Prior to integration, the substrate-bound Cas1-Cas2 complex must locate the CRISPR leader-
117 repeat sequence. Adaptation complexes of several systems display intrinsic affinity for the leader-
118 repeat region in vitro (36, 43), yet this is not always wholly sufficient to provide the specificity
119 observed in vivo. For the type I-E system, leader-repeat recognition is assisted by the integration
120 host factor (IHF) heterodimer, which binds in the leader (44). IHF binds DNA in a sequence-
121 specific manner and induces ~120° DNA bending, providing a cue to accurately localize Cas1-
122 Cas2 to the leader-repeat junction (44, 45). A conserved leader motif upstream of the IHF pivot is
123 proposed to stabilize the Cas1-Cas2-leader-repeat interaction and increase adaptation efficiency,
124 supporting bipartite binding of the adaptation complex to DNA sites either side of bound IHF (45).

125 IHF is absent in many prokaryotes, including archaea and gram-positive bacteria, suggesting other
126 leader-proximal integration mechanisms exist. Indeed, type II-A Cas1-Cas2 from *Streptococcus*
127 *pyogenes* catalyzed leader-proximal integration in vitro, at a level of precision comparable to the
128 type I-E system with IHF (43, 44). Hence, type II-A systems may rely solely on intrinsic sequence
129 specificity for the leader-repeat. A short leader-anchoring site (LAS) adjacent to the first repeat
130 and ≤6 bp of this repeat were essential for adaptation (22, 38, 43) and are conserved in systems
131 with similar repeats. Placement of an additional LAS in front of a non-leader repeat resulted in
132 adaptation at both sites (38), whereas LAS deletion caused ectopic integration at a downstream
133 repeat adjacent to a spacer containing a LAS-like sequence (22). Taken together, this shows
134 specific sequences upstream of CRISPR arrays direct leader-polarized spacer integration, both via
135 direct Cas1-Cas2 recognition and assisted by host proteins, such as IHF.

136



137


138 **Fig. 2: Cas1-Cas2-mediated spacer acquisition.** The substrate loaded Cas1-Cas2 protein
 139 complex (*E. coli* type I-E structure shown top left; PDB 5DQZ) with the active PAM sensing
 140 domain highlighted (light purple) and a partially duplexed DNA pre-spacer substrate (strands are
 141 purple and pink) (41, 42). The Cas1 PAM sensing insert shows the canonical type I-E PAM (CTT),
 142 residue-specific interactions (a residue from the non-catalytic Cas1 monomer is annotated with *),
 143 and site of PAM processing (scissors). The ruler mechanism determining spacer length for the type
 144 I-E systems uses two conserved tyrosine residues (grey hexagons). Spacer integration proceeds as
 145 follows: 1) the Cas1-Cas2:pre-spacer complex binds the leader (green) and first repeat (black). 2)
 146 The first nucleophilic attack occurs at the leader-repeat junction and gives rise to a half-site
 147 intermediate. 3) The second nucleophilic attack occurs at the repeat-spacer (orange)
 148 boundary resulting in full site integration. The type I-E repeat is magnified (lower left) to indicate the
 149 inverted repeats within its sequence and highlight the anchoring sites of the molecular rulers that
 150 determine the point of integration. 4) Host DNA repair enzymes fill the intergration site. For
 151 additional details, see the text.

152

153 *Integration into the CRISPR array*

154 In almost all types of CRISPR-Cas systems, the presence of a short sequence motif in the target
155 nucleic acid adjacent to where the crRNA basepairs is essential for interference (the target-strand
156 that the crRNA pairs to is known as the protospacer) (**Fig. 3**) (46). This sequence motif is termed
157 a protospacer adjacent motif (PAM) and is a key feature for spacer selection during adaptation (17,
158 27, 47, 48). Acquisition of interference-proficient spacers requires processing of the pre-spacer
159 substrate at a specific position relative to a PAM and also integration into the CRISPR array in the
160 correct orientation. The active site of each Cas1 monomer contains a PAM sensing domain (41,
161 42) and the presence of a PAM within the pre-spacer substrate ensures integration in the
162 appropriate orientation (49-51). Accordingly, PAM proximal processing, resulting in complete or
163 partial (in the case of type I-E) removal of the PAM, is likely to occur after Cas1-Cas2 orients and
164 docks at the leader-repeat. In contrast, if complete processing occurred before docking to the
165 CRISPR locus, then the PAM directionality cue would be lost. Cas1-mediated processing of the
166 pre-spacer creates two 3'OH ends required for nucleophilic attack on each strand of the leader-
167 proximal repeat (36, 37, 52). The initial nucleophilic attack most likely occurs at the leader-repeat
168 junction and forms a half-site intermediate, then a second attack at the existing repeat-spacer
169 junction generates the full-site integration product (**Fig. 2**). The precise order of the pre-spacer
170 processing and integration steps remains to be fully determined, yet considerable progress toward
171 elucidating the reaction mechanisms has been made.

172 Following the first nucleophilic attack, Cas1-Cas2 employs molecular rulers that harness the
173 intrinsic sequence-specificity of the complex to define the site of the second attack and ensure
174 accurate repeat length duplication. CRISPR repeats are often semi-palindromic, containing two
175 short inverted repeat (IR) elements, but the location of these can vary (53). In type I-B and I-E
176 systems, the IRs occur close to the center of the repeat (**Fig. 2**) and are important for adaptation
177 (54, 55). In the type I-E system, both IRs act as anchors for the Cas1-Cas2 complex, positioning
178 the active site for the second attack at the repeat-spacer boundary (54). However, in the type I-B
179 system from *Haloarcula hispanica*, only the first IR was essential for integration, and thus a single
180 molecular ruler directed by an anchor between the IRs was proposed (55). In contrast, in the type
181 II-A systems of *Streptococcus thermophilus* and *S. pyogenes* the IRs are located distally within the
182 repeats, suggesting these short sequences may directly position the nucleophilic attacks without
183 molecular rulers (38, 43). Although further work is required to determine how the spacer
184 integration events are directed in different CRISPR-Cas systems, it seems likely the conserved
185 leader-repeat regions at the beginning of CRISPR arrays maintain recognizable sequences to
186 ensure Cas1-Cas2 localizes appropriately and spacer insertion and repeat duplication is of the
187 correct length.



188
189

190 **Fig. 3: Target interactions and the PAMs of different CRISPR-Cas types.** DNA targets are
 191 recognized by the crRNA-effector complexes of types I, II and V, resulting in formation of an R-
 192 loop with the non-target strand displaced. The target strand contains the protospacer (red), which
 193 is complementary to the spacer (crRNA, orange) sequence. The protospacer adjacent motif (PAM,
 194 blue) is located at either the 3' end of the protospacer (type I and type V) or the 5' end (type II).
 195 The PAM assignment is consistent with target-centric nomenclature (46). Type III and VI
 196 recognize RNA targets, with type III exhibiting transcription-dependent DNA targeting. Some type
 197 III systems require an RNA-based PAM (rPAM). Type VI systems exhibit a protospacer flanking
 198 sequence (PFS) specificity, which is analogous to a PAM.

199

200 ***Production of spacers from foreign DNA***


201 *Naïve adaptation*

202 Acquisition of spacers from MGEs that are not already catalogued in host CRISPRs is termed
 203 naïve adaptation (56) (**Fig. 4**). To facilitate naïve adaptation, pre-spacer substrates are generated
 204 from foreign material and loaded onto Cas1-Cas2. Currently, the main known source of these
 205 precursors is the host RecBCD complex (57). Stalled replication forks that occur during DNA
 206 replication can result in double strand breaks (DSBs), which are repaired via RecBCD-mediated
 207 unwinding and degradation of the dsDNA ends back to the nearest Chi sites (58). During this
 208 process, RecBCD produces ssDNA fragments that are proposed to anneal, forming substrates
 209 suitable for use by Cas1-Cas2 (57). Loading of substrates into Cas1-Cas2 is likely enhanced by
 210 interaction between Cas1 and RecBCD (59), positioning the adaptation machinery adjacent to the
 211 site of substrate generation. The increased number of active origins of replication and the paucity
 212 of Chi sites on MGEs, versus the host chromosome, biases naïve adaptation toward foreign DNA.
 213 Furthermore, RecBCD recognizes unprotected dsDNA ends, which are commonly present in

214 phage genomes upon injection or prior to packaging, thereby providing an additional phage-
215 specific source of naïve adaptation substrates (57, 60).

216 Despite the clear role of RecBCD in substrate generation, naïve adaptation also occurs in its
217 absence, albeit with reduced bias toward foreign DNA (57). Events other than DSBs might also
218 stimulate naïve adaptation, such as R-loops that prime plasmid replication (61), lagging ends of
219 incoming conjugative elements (62), and even CRISPR-Cas mediated spacer integration events
220 themselves (51, 57). Furthermore, it is unknown whether all CRISPR-Cas systems display an
221 intrinsic adaptation bias towards foreign DNA. Complicating results, spacer acquisition from the
222 host genome in native systems could be underestimated because the resulting self-targeting means
223 these genotypes are typically lethal (32, 33, 51, 63). For example, in the *S. thermophilus* type II-A
224 system, adaptation appears biased toward MGEs, yet nuclease-deficient Cas9 (dCas9) failed to
225 discriminate between acquisition from host versus foreign DNA (63) and it is unknown whether
226 the adaptation was reliant on DNA break repair. Further studies in a range of host systems are
227 required to clarify how diverse CRISPR-Cas systems balance the requirement for naïve adaptation
228 from MGEs against the risk of self-acquisition events.

229



230

231 **Fig. 4: Cas1-Cas2 substrate production pathways.** 1) Naïve generation of substrates by
232 RecBCD activity on DNA ends resulting from DSBs from stalled replication forks, innate defenses
233 such as restriction endonuclease activity or from the ends of phage genomes (not shown). 2)
234 Primed substrate production in type I systems. 3) Cas9-dependent spacer selection in type II
235 systems. For details, see the text.

236

237 *crRNA-directed adaptation (Priming)*

238 Mutations in the target PAM or protospacer sequences can abrogate immunity, allowing MGEs to
239 escape CRISPR-Cas defenses (47, 64, 65). Furthermore, the immunological effectiveness of
240 individual spacers varies: often several target-specific spacers are required to both mount an
241 effective defense (66, 67) and prevent proliferation of MGE escape mutants (13, 14). Thus,
242 CRISPR-Cas systems need to adapt faster than the foreign element can evade targeting. Indeed,

243 type I systems have evolved a mechanism known as primed adaptation (priming) to facilitate rapid
244 CRISPR adaptation (68, 69), even against highly divergent invaders (65) (**Fig. 4**). In contrast to
245 naïve adaptation, priming utilizes target recognition by crRNAs from pre-existing spacers to direct
246 spacer acquisition toward invaders whose proliferation exceeds the existing defense capabilities.
247 This often occurs with MGE escape mutants, but also when the CRISPR-Cas expression level is
248 insufficient to provide immunity – even with spacers perfectly targeting the MGE (65, 68-72).

249 Priming begins with target recognition by crRNA-effector complexes. Therefore, factors that
250 influence target recognition (i.e. the formation and stability of the R-loop – see **Fig. 3**), including
251 PAM sensing and crRNA:target complementarity, affect the efficiency of primed adaptation (64,
252 65, 67, 73-80). Furthermore, these same factors influence conformational rearrangements in the
253 target-bound crRNA-effector complex, coalescing to favor either interference or priming (67, 74,
254 75, 78, 81). In type I-E systems, the Cas8e (Cse1) subunit of Cascade can adopt one of two
255 conformational modes (78, 81), which may promote either direct or Cas1-Cas2-stimulated
256 recruitment of the effector Cas3 nuclease (74, 75, 81).


257 Cas3, found in all type I systems, exhibits 3' to 5' helicase and endonuclease activity that nicks,
258 unwinds and degrades target DNA (82-85). In vitro activity of the type I-E Cas3 produces ssDNA
259 fragments of ~30-100 nucleotides that are enriched for PAMs in their 3' ends, which anneal to
260 provide partially duplexed pre-spacer substrates (73). The spatial positioning of Cas1-Cas2 during
261 primed substrate generation has not been clearly established, although Cas1-Cas2-facilitated
262 recruitment of Cas3 would imply the adaptation machinery is localized close to the site of substrate
263 production (74, 81). In support of this, Cas3 in type I-F systems is fused to the C-terminus of Cas2
264 and forms a Cas1-Cas2-3 complex (35) that couples the adaptation machinery directly to the source
265 of substrate generation during primed adaptation (51, 86).

266 Despite different crRNA-effector:target interactions favoring distinct Cas3 recruitment modes,
267 primed adaptation can occur from both escape mutants and interference-proficient targets (51, 68,
268 69, 87). When target copy-number influences are excluded for type I-E and type I-F systems,
269 interference-proficient targets promote stronger spacer acquisition than escape targets (51, 87).
270 This provides a positive feedback loop, reinforcing immunity against recurrent threats even in the
271 absence of escapees (51, 69). However, because target interference rapidly destroys the invader,
272 more spacer acquisition is provoked by escape mutants where replication of the MGE outpaces its
273 destruction. Over time, the prolonged presence of the invader, combined with the priming-centric
274 target recognition mode, results in higher net production of pre-spacer substrates from escape
275 mutants (51, 72, 73, 87).

276 Because priming initiates with site-specific target recognition (i.e. targeting a 'priming'
277 protospacer), Cas1-Cas2 compatible substrates are subsequently produced from MGEs with
278 locational biases (**Fig. 5**). Mapping the MGE sequence positions and strands targeted by newly
279 acquired spacers (i.e. their corresponding protospacers) revealed subtype-specific patterns and has
280 provided much of our insight into the priming mechanisms (50, 51, 68, 69, 86, 88, 89). In type I-
281 E systems, new protospacers map to the same strand (50, 69) as the priming protospacer (**Fig. 5**).
282 For type I-B priming, Cas3 is predicted to load onto either strand at the priming protospacer,
283 resulting in a bidirectional distribution of new protospacers (88). For type I-F priming, the first
284 new protospacer typically maps to the strand opposite the priming protospacer, in a direction
285 consistent with Cas3 loading and helicase activity on the non-target strand. Furthermore, once the
286 first spacer is acquired, two targets in the MGE will be recognized and substrate production can
287 be driven from both locations (51, 86) (**Fig. 5**). However, in a head-to-head contest interference-

288 proficient targets dominate, thus, subsequent spacers (i.e. the second and beyond) generally result
 289 from targeting by the first new spacer and are typically located back towards the original priming
 290 protospacer(51) (**Fig. 5**). The dominance of the first new spacer also holds true for type I-E (69,
 291 87) and likely all other systems that display priming. However, these are generalized models and
 292 many questions remain unresolved, such as the mechanisms resulting in strand selection and why
 293 some spacer sequences are more highly acquired from MGEs than others. Further analyses of
 294 priming in different systems, particularly the order of new spacers acquired, will greatly inform
 295 our understanding of primed Cas1-Cas2 substrate production.

296



297

298

299 **Fig. 5: Primed adaptation from a multi-copy MGE by type I-E and I-F CRISPR-Cas systems.**
 300 1) An existing spacer (purple) with homology to an MGE sequence that has escaped interference
 301 (the ‘priming’ protospacer denoted with an asterisk) directs target recognition – the PAM adjacent
 302 to the protospacer is shown in black (PAMs at the right or left of protospacers indicate the strand
 303 each protospacer is on). The crRNA-effector complex recruits Cas3 and the 3’ to 5’ helicase
 304 activity (illustrated by the red arrow) results in the acquisition of a new spacer that maps to a
 305 protospacer (orange) from a site distal to the initial priming location. 2) The new interference-
 306 proficient spacer directs targeting of the MGE and recruitment of Cas3. Hence, subsequent spacers
 307 (mapping to blue protospacers) typically originate from Cas3 activity (red arrows) beginning at
 308 this location. See text for details.

309

310 *Cas protein-assisted production of spacers*

311 Given the apparent advantages conferred by priming in type I systems, mechanisms to utilize
 312 existing spacers to direct adaptation are likely to exist in other CRISPR-Cas types. For example,
 313 DNA breaks induced by interference activity of class 2 CRISPR-Cas effector complexes could
 314 trigger host DNA repair mechanisms (e.g. RecBCD), thereby providing substrates for Cas1-Cas2.
 315 In agreement with a generalized DNA break-stimulated adaptation model, restriction enzyme
 316 activity stimulated RecBCD-facilitated adaptation (57). This may also partially account for the
 317 enhanced adaptation observed during phage infection of a host possessing an innate defense

318 restriction-modification system (31), but whether this was RecBCD-dependent is unknown. For
319 CRISPR-Cas-induced DNA breaks, spacer acquisition would be preceded by target recognition,
320 hence the resulting adaptation could be considered related to ‘priming’ (90). Although direct
321 evidence to support this concept is lacking, adaptation in type II-A systems requires Cas1-Cas2,
322 Cas9, a tracrRNA and Csn2 (63, 90). In support of a role for Cas9 in substrate generation, the
323 PAM-sensing domain of Cas9 enhances the acquisition of spacers with compatible PAMs (90).
324 However, Cas9 nuclease activity is dispensable (63) and existing spacers are not strictly necessary
325 (90), suggesting that PAM interactions of Cas9 could be sufficient to select appropriate new
326 spacers. Some Cas9 variants can also function with non-CRISPR RNAs and tracrRNA (91), raising
327 the possibility that host or MGE-derived RNAs might direct promiscuous Cas9 activity, resulting
328 in DNA breaks, or replication fork stalling and trigger spacer integration.

329

330 ***Roles of accessory Cas proteins in adaptation***

331 Although Cas1 and Cas2 play a central role in adaptation, type-specific variations in *cas* gene
332 clusters occur. In many systems, Cas1-Cas2 is assisted by accessory Cas proteins, which are often
333 mutually exclusive and type-specific (4). For example, in the *S. thermophilus* type II-A system,
334 deletion of *csn2* impaired the acquisition of spacers from invading phages (6). Csn2 assembles into
335 ring-shaped homo-tetramers with a calcium-stabilized central channel (92, 93) that binds
336 cooperatively to the free ends of linear dsDNA and can translocate by rotation-coupled movement
337 (94, 95). Given that substrate-loaded type II-A Cas1-Cas2 is capable of full-site spacer integration
338 in vitro (43), Csn2 is likely to play an earlier role in either pre-spacer substrate production,
339 selection or processing. Potentially, Csn2 binding to the free ends of dsDNA provides a cue to
340 direct nucleases necessary for substrate generation (94).

341 Cas4, another ring-forming accessory protein, is found in type I, II-B and V systems (4).
342 Confirming its role in adaptation, Cas4 is necessary for type I-B priming in *H. hispanica* (88) and
343 interacts with a Cas1-2 fusion protein in the *Thermoproteus tenax* type I-A system (96). Fusions
344 between Cas4 and Cas1 are found in several systems, supporting a functional association with
345 adaptation. Cas4 contains a RecB-like domain and four conserved cysteine residues, which are
346 presumably involved in the coordination of an iron-sulfur cluster (97). However, Cas4 proteins
347 appear to be functionally diverse with some possessing uni- or bi-directional exonuclease activity
348 (97, 98), while others exhibit ssDNA endonuclease activity and unwinding activity on dsDNA
349 (98). Due to its nuclease activity, Cas4 is hypothesized to trim pre-spacer substrates and aid
350 adaptation by generating 3’ overhangs in the duplex pre-spacer substrate.

351 To provide immunity, type III systems require spacers complementary to RNA transcribed from
352 MGEs (Fig. 3) (99, 100). Some bacterial type III systems contain fusions of Cas1 with reverse
353 transcriptase domains (RTs), which provide a mechanism to integrate spacers from RNA substrates
354 (101). The RT-Cas1 fusion from *M. mediterranea* can integrate RNA precursors into an array,
355 which are subsequently reverse transcribed to generate DNA spacers (101). However, integration
356 of DNA-derived spacers also occurs, indicating that the RNA derived-spacer route is not exclusive
357 (101). Hence, the integrase activity of RT-Cas1-Cas2 is extended by the reverse transcriptase
358 activity, enabling enhanced build-up of immunity against highly transcribed DNA MGEs and
359 potentially from RNA-based invaders.

360 Despite evidence that accessory Cas proteins are involved in spacer acquisition, their roles mostly
361 remain elusive. Furthermore, other host proteins may also be required for pre-spacer substrate

362 production. For example, RecG is required for efficient primed adaptation in type I-E and I-F
363 systems, but its precise role remains speculative (39, 102). Additionally, it remains enigmatic why
364 some CRISPR-Cas systems appear to require accessory proteins, whilst closely related types do
365 not. For example, type II-C systems lack *cas4* or *csn2* that assist in type II-A and II-B adaptation,
366 respectively. These type-specific differences exemplify the diversity that has arisen during
367 evolution of CRISPR-Cas systems.

368

369 ***Evolution of adaptation***

370 The expanding knowledge of spacer integration has led to a promising theory for the evolutionary
371 origin of CRISPR-Cas systems (103). Casposons are transposon-like elements typified by the
372 presence of Cas1 homologs, casposases, which catalyze site-specific DNA integration and result
373 in the duplication of repeat sites analogous to CRISPR adaptation (104, 105). It is proposed that
374 ancestral innate defenses gained DNA integration functionality from casposases, seeding the
375 genesis of prokaryotic adaptive immunity (106). The innate ancestor remains to be determined,
376 but is likely to be a nuclease-based system. Co-occurrence of casposon-derived terminal inverted
377 repeats and casposases in the absence of full casposons might represent an intermediate of the
378 CRISPR signature repeat-spacer-repeat structures (107). However, the evolutionary journey from
379 the innate immunity-casposase hybrid to full adaptive immunity remains unclear. Nevertheless,
380 comparative genomics indicate that all known CRISPR-Cas systems evolved from a single
381 ancestor (4, 5).

382 The more compact class 2 CRISPR-Cas systems likely evolved from class 1 ancestors, through
383 acquisition of genes encoding new single-subunit effector proteins and loss of additional *cas* genes
384 (5). Evolution of CRISPR-Cas types would have required stringent co-evolution of the adaptation
385 machinery, leader-repeat sequences (108), crRNA processing mechanisms and effector complex
386 function. However, despite the subsequent divergence of CRISPR-Cas systems into several types,
387 Cas1-Cas2 remains the workhorse of spacer acquisition, central to the success of CRISPR-Cas
388 systems (4, 5). As long as spacers can be acquired from MGEs, unique effector machineries
389 capable of utilizing the information stored in CRISPRs will continue to evolve.

390 Mechanisms to generate Cas1-Cas2 compatible substrates, such as primed adaptation might have
391 arisen because naïve acquisition is an inefficient and undirected process, potentially leading to
392 high rates of lethal self-targeting spacers. However, despite the apparent advantages of primed
393 adaptation, it was recently reported that promiscuous binding of crRNA-effector complexes to the
394 host genome results in a basal level of self-priming, the extent of which is likely underrepresented
395 due to the lethality of such events (51). Host *cas* gene regulation mechanisms have arisen to
396 balance the likelihood of self-acquisition events against the requirement to adapt to new threats,
397 for example, when the risk of phage infection or HGT is high (109, 110). Alternatively, it has been
398 proposed that selective acquisition of self-targeting spacers could provide benefits such as
399 invoking altruistic cell death (111), rapid genome evolution (33), regulation of host processes (112,
400 113), or even preventing the uptake of other CRISPR-Cas systems (114).

401

402 **Outlook**

403 The past four years has seen rapid progress to understand the adaptation phase of CRISPR-Cas
404 immunity. Despite this progress, many facets of CRISPR adaptation require further attention.

405 Synergy between innate defense systems and adaptation is relatively unexplored, but two roles can
406 be envisioned; DNA breaks (57) stimulating generation of substrates for spacer acquisition (**Fig.**
407 **4**) or stalling of infection to ‘buy time’ for adaptation (31, 115, 116). Analogously, it remains to
408 be determined whether interference by CRISPR-Cas systems other than type I can also stimulate
409 primed adaptation. If not, the benefits of priming might provide an explanation for why type I
410 systems are more prevalent than other types.

411 It is also unclear why many CRISPR-Cas systems have multiple arrays used by a single set of Cas
412 proteins, rather than a solo array. Given that Cas1-Cas2 is directed to leader-repeat junctions
413 during integration, multiple arrays might provide additional integration sites, increasing adaptation
414 efficiency. In addition, parallel CRISPR arrays should increase crRNA production from recently
415 acquired spacers (i.e. due to polarization) (22). Whereas some strains have multiple CRISPR arrays
416 belonging to the same type, other hosts have several types of CRISPR-Cas systems simultaneously
417 (117). The benefits of harboring multiple CRISPR-Cas systems are not entirely clear, but can result
418 in spacers used by different system to extend targeting to both RNA and DNA (118). From an
419 adaptation perspective, multiple systems might enable a wider PAM repertoire to be sampled
420 during spacer selection. Additional systems in a single host could also be a response to defy phage-
421 and MGE-encoded anti-CRISPR proteins, which can inhibit both interference and primed
422 adaptation (119-121), or may allow some systems to function in defense, while others perform
423 non-canonical roles in gene regulation (113).

424 While Cas effector nucleases (e.g. Cas9) have been harnessed for many biotechnological
425 applications, the use of repurposed CRISPR-Cas adaptation machinery has yet to be widely
426 exploited. The sequence-specific integrase activity holds promise in synthetic biology, such as for
427 the insertion of specific sequences (or barcodes) to mark and track cells in a population. In *E. coli*
428 the feasibility of such an approach is evident (49), but transition to eukaryotic systems will provide
429 the greatest utility where lineage tracking and cell fate could be followed, as has been performed
430 with Cas9 (122). The elements required for leader-specific integration must be carefully
431 considered for the introduction of CRISPR-Cas adaptation into eukaryotic cells, as unintended
432 ectopic integrations could be problematic given the larger eukaryotic sequence space. Ultimately,
433 our understanding of adaptation in prokaryotes may lead to applications where entire CRISPR
434 systems are transplanted into eukaryotic cells to prevent viral invaders. As we begin to comprehend
435 adaptation in more detail the opportunities to repurpose other parts of these remarkable prokaryotic
436 immune systems is increasingly becoming reality.

437

438 **References and Notes:**

- 439
- 440 1. R. L. Dy, C. Richter, G. P. Salmond, P. C. Fineran, Remarkable Mechanisms in Microbes to
441 Resist Phage Infections. *Annu Rev Virol* **1**, 307-331 (2014).
- 442 2. J. E. Samson, A. H. Magadán, M. Sabri, S. Moineau, Revenge of the phages: defeating bacterial
443 defences. *Nat Rev Microbiol* **11**, 675-687 (2013).
- 444 3. L. A. Marraffini, CRISPR-Cas immunity in prokaryotes. *Nature* **526**, 55-61 (2015).
- 445 4. K. S. Makarova *et al.*, An updated evolutionary classification of CRISPR-Cas systems. *Nat Rev*
446 *Microbiol* **13**, 722-736 (2015).
- 447 5. P. Mohanraju *et al.*, Diverse evolutionary roots and mechanistic variations of the CRISPR-Cas
448 systems. *Science* **353**, aad5147 (2016).
- 449 6. R. Barrangou *et al.*, CRISPR provides acquired resistance against viruses in prokaryotes. *Science*
450 **315**, 1709-1712 (2007).
- 451 7. S. J. Brouns *et al.*, Small CRISPR RNAs guide antiviral defense in prokaryotes. *Science* **321**,
452 960-964 (2008).
- 453 8. A. V. Wright, J. K. Nuñez, J. A. Doudna, Biology and Applications of CRISPR Systems:
454 Harnessing Nature's Toolbox for Genome Engineering. *Cell* **164**, 29-44 (2016).
- 455 9. G. Amitai, R. Sorek, CRISPR-Cas adaptation: insights into the mechanism of action. *Nat Rev*
456 *Microbiol* **14**, 67-76 (2016).
- 457 10. S. H. Sternberg, H. Richter, E. Charpentier, U. Qimron, Adaptation in CRISPR-Cas Systems. *Mol*
458 *Cell* **61**, 797-808 (2016).
- 459 11. M. J. Lopez-Sanchez *et al.*, The highly dynamic CRISPR1 system of *Streptococcus agalactiae*
460 controls the diversity of its mobilome. *Mol Microbiol* **85**, 1057-1071 (2012).
- 461 12. G. W. Tyson, J. F. Banfield, Rapidly evolving CRISPRs implicated in acquired resistance of
462 microorganisms to viruses. *Environ Microbiol* **10**, 200-207 (2008).
- 463 13. A. F. Andersson, J. F. Banfield, Virus population dynamics and acquired virus resistance in
464 natural microbial communities. *Science* **320**, 1047-1050 (2008).
- 465 14. S. van Houte *et al.*, The diversity-generating benefits of a prokaryotic adaptive immune system.
466 *Nature* **532**, 385-388 (2016).
- 467 15. C. Pourcel, G. Salvignol, G. Vergnaud, CRISPR elements in *Yersinia pestis* acquire new repeats
468 by preferential uptake of bacteriophage DNA, and provide additional tools for evolutionary
469 studies. *Microbiology* **151**, 653-663 (2005).
- 470 16. F. Liu *et al.*, Novel virulence gene and clustered regularly interspaced short palindromic repeat
471 (CRISPR) multilocus sequence typing scheme for subtyping of the major serovars of *Salmonella*
472 *enterica* subsp. *enterica*. *Appl Environ Microbiol* **77**, 1946-1956 (2011).
- 473 17. I. Yosef, M. G. Goren, U. Qimron, Proteins and DNA elements essential for the CRISPR
474 adaptation process in *Escherichia coli*. *Nucleic Acids Res* **40**, 5569-5576 (2012).
- 475 18. C. Díez-Villaseñor, N. M. Guzmán, C. Almendros, J. García-Martínez, F. J. Mojica, CRISPR-
476 spacer integration reporter plasmids reveal distinct genuine acquisition specificities among
477 CRISPR-Cas I-E variants of *Escherichia coli*. *RNA Biol* **10**, 792-802 (2013).
- 478 19. S. Erdmann, R. A. Garrett, Selective and hyperactive uptake of foreign DNA by adaptive immune
479 systems of an archaeon via two distinct mechanisms. *Mol Microbiol* **85**, 1044-1056 (2012).
- 480 20. C. L. Sun, B. C. Thomas, R. Barrangou, J. F. Banfield, Metagenomic reconstructions of bacterial
481 CRISPR loci constrain population histories. *ISME J* **10**, 858-870 (2016).
- 482 21. D. Paez-Espino *et al.*, Uncovering Earth's virome. *Nature* **536**, 425-430 (2016).
- 483 22. J. McGinn, L. A. Marraffini, CRISPR-Cas Systems Optimize Their Immune Response by
484 Specifying the Site of Spacer Integration. *Mol Cell* **64**, 616-623 (2016).
- 485 23. Y. Zhang *et al.*, Processing-independent CRISPR RNAs limit natural transformation in *Neisseria*
486 *meningitidis*. *Mol Cell* **50**, 488-503 (2013).

- 487 24. A. Biswas, R. H. Staals, S. E. Morales, P. C. Fineran, C. M. Brown, CRISPRDetect: A flexible
488 algorithm to define CRISPR arrays. *BMC Genomics* **17**, 356 (2016).
- 489 25. P. Horvath *et al.*, Diversity, activity, and evolution of CRISPR loci in *Streptococcus*
490 *thermophilus*. *J Bacteriol* **190**, 1401-1412 (2008).
- 491 26. F. J. Mojica, C. Díez-Villaseñor, J. García-Martínez, E. Soria, Intervening sequences of regularly
492 spaced prokaryotic repeats derive from foreign genetic elements. *J Mol Evol* **60**, 174-182 (2005).
- 493 27. A. Bolotin, B. Quinquis, A. Sorokin, S. D. Ehrlich, Clustered regularly interspaced short
494 palindrome repeats (CRISPRs) have spacers of extrachromosomal origin. *Microbiology* **151**,
495 2551-2561 (2005).
- 496 28. K. S. Makarova, N. V. Grishin, S. A. Shabalina, Y. I. Wolf, E. V. Koonin, A putative RNA-
497 interference-based immune system in prokaryotes: computational analysis of the predicted
498 enzymatic machinery, functional analogies with eukaryotic RNAi, and hypothetical mechanisms
499 of action. *Biol Direct* **1**, 7 (2006).
- 500 29. L. A. Marraffini, E. J. Sontheimer, CRISPR interference limits horizontal gene transfer in
501 staphylococci by targeting DNA. *Science* **322**, 1843-1845 (2008).
- 502 30. S. T. Abedon, Facilitation of CRISPR adaptation. *Bacteriophage* **1**, 179-181 (2011).
- 503 31. A. P. Hynes, M. Villion, S. Moineau, Adaptation in bacterial CRISPR-Cas immunity can be
504 driven by defective phages. *Nat Commun* **5**, 4399 (2014).
- 505 32. A. Stern, L. Keren, O. Wurtzel, G. Amitai, R. Sorek, Self-targeting by CRISPR: gene regulation
506 or autoimmunity? *Trends Genet* **26**, 335-340 (2010).
- 507 33. R. B. Vercoe *et al.*, Cytotoxic chromosomal targeting by CRISPR/Cas systems can reshape
508 bacterial genomes and expel or remodel pathogenicity islands. *PLoS Genet* **9**, e1003454 (2013).
- 509 34. J. K. Nuñez *et al.*, Cas1-Cas2 complex formation mediates spacer acquisition during CRISPR-
510 Cas adaptive immunity. *Nat Struct Mol Biol* **21**, 528-534 (2014).
- 511 35. C. Richter, T. Gristwood, J. S. Clulow, P. C. Fineran, In vivo protein interactions and complex
512 formation in the *Pectobacterium atrosepticum* subtype I-F CRISPR/Cas System. *PLoS One* **7**,
513 e49549 (2012).
- 514 36. J. K. Nuñez, A. S. Lee, A. Engelman, J. A. Doudna, Integrase-mediated spacer acquisition during
515 CRISPR-Cas adaptive immunity. *Nature* **519**, 193-198 (2015).
- 516 37. Z. Arslan, V. Hermanns, R. Wurm, R. Wagner, U. Pul, Detection and characterization of spacer
517 integration intermediates in type I-E CRISPR-Cas system. *Nucleic Acids Res* **42**, 7884-7893
518 (2014).
- 519 38. Y. Wei, M. T. Chesne, R. M. Terns, M. P. Terns, Sequences spanning the leader-repeat junction
520 mediate CRISPR adaptation to phage in *Streptococcus thermophilus*. *Nucleic Acids Res* **43**, 1749-
521 1758 (2015).
- 522 39. I. Ivančić-Baće, S. D. Cass, S. J. Wearne, E. L. Bolt, Different genome stability proteins underpin
523 primed and naive adaptation in *E. coli* CRISPR-Cas immunity. *Nucleic Acids Res* **43**, 10821-
524 10830 (2015).
- 525 40. B. Wiedenheft *et al.*, Structural basis for DNase activity of a conserved protein implicated in
526 CRISPR-mediated genome defense. *Structure* **17**, 904-912 (2009).
- 527 41. J. Wang *et al.*, Structural and Mechanistic Basis of PAM-Dependent Spacer Acquisition in
528 CRISPR-Cas Systems. *Cell* **163**, 840-853 (2015).
- 529 42. J. K. Nuñez, L. B. Harrington, P. J. Kranzusch, A. N. Engelman, J. A. Doudna, Foreign DNA
530 capture during CRISPR-Cas adaptive immunity. *Nature* **527**, 535-538 (2015).
- 531 43. A. V. Wright, J. A. Doudna, Protecting genome integrity during CRISPR immune adaptation. *Nat*
532 *Struct Mol Biol* **23**, 876-883 (2016).
- 533 44. J. K. Nuñez, L. Bai, L. B. Harrington, T. L. Hinder, J. A. Doudna, CRISPR Immunological
534 Memory Requires a Host Factor for Specificity. *Mol Cell* **62**, 824-833 (2016).
- 535 45. K. N. Yoganand, R. Sivathanu, S. Nimkar, B. Anand, Asymmetric positioning of Cas1-2 complex
536 and Integration Host Factor induced DNA bending guide the unidirectional homing of
537 protospacer in CRISPR-Cas type I-E system. *Nucleic Acids Res*, (2016).

- 538 46. R. T. Leenay, C. L. Beisel, Deciphering, communicating, and engineering the CRISPR PAM. *J*
539 *Mol Biol*, (2016).
- 540 47. H. Deveau *et al.*, Phage response to CRISPR-encoded resistance in *Streptococcus thermophilus*. *J*
541 *Bacteriol* **190**, 1390-1400 (2008).
- 542 48. F. J. Mojica, C. Díez-Villaseñor, J. García-Martínez, C. Almendros, Short motif sequences
543 determine the targets of the prokaryotic CRISPR defence system. *Microbiology* **155**, 733-740
544 (2009).
- 545 49. S. L. Shipman, J. Nivala, J. D. Macklis, G. M. Church, Molecular recordings by directed CRISPR
546 spacer acquisition. *Science* **353**, aaf1175 (2016).
- 547 50. S. Shmakov *et al.*, Pervasive generation of oppositely oriented spacers during CRISPR
548 adaptation. *Nucleic Acids Res* **42**, 5907-5916 (2014).
- 549 51. R. H. Staals *et al.*, Interference-driven spacer acquisition is dominant over naive and primed
550 adaptation in a native CRISPR-Cas system. *Nat Commun* **7**, 12853 (2016).
- 551 52. C. Rollie, S. Schneider, A. S. Brinkmann, E. L. Bolt, M. F. White, Intrinsic sequence specificity
552 of the CasI integrase directs new spacer acquisition. *Elife* **4**, (2015).
- 553 53. V. Kunin, R. Sorek, P. Hugenholtz, Evolutionary conservation of sequence and secondary
554 structures in CRISPR repeats. *Genome Biol* **8**, R61 (2007).
- 555 54. M. G. Goren *et al.*, Repeat Size Determination by Two Molecular Rulers in the Type I-E CRISPR
556 Array. *Cell Rep* **16**, 2811-2818 (2016).
- 557 55. R. Wang, M. Li, L. Gong, S. Hu, H. Xiang, DNA motifs determining the accuracy of repeat
558 duplication during CRISPR adaptation in *Haloarcula hispanica*. *Nucleic Acids Res* **44**, 4266-
559 4277 (2016).
- 560 56. P. C. Fineran, E. Charpentier, Memory of viral infections by CRISPR-Cas adaptive immune
561 systems: acquisition of new information. *Virology* **434**, 202-209 (2012).
- 562 57. A. Levy *et al.*, CRISPR adaptation biases explain preference for acquisition of foreign DNA.
563 *Nature* **520**, 505-510 (2015).
- 564 58. D. B. Wigley, Bacterial DNA repair: recent insights into the mechanism of RecBCD, AddAB and
565 AdnAB. *Nat Rev Microbiol* **11**, 9-13 (2013).
- 566 59. M. Babu *et al.*, A dual function of the CRISPR-Cas system in bacterial antiviral immunity and
567 DNA repair. *Mol Microbiol* **79**, 484-502 (2011).
- 568 60. L. W. Enquist, A. Skalka, Replication of bacteriophage lambda DNA dependent on the function
569 of host and viral genes. I. Interaction of red, gam and rec. *J Mol Biol* **75**, 185-212 (1973).
- 570 61. J. Gowrishankar, J. K. Leela, K. Anupama, R-loops in bacterial transcription: their causes and
571 consequences. *Transcription* **4**, 153-157 (2013).
- 572 62. E. R. Westra *et al.*, CRISPR-Cas systems preferentially target the leading regions of MOBF
573 conjugative plasmids. *RNA Biol* **10**, 749-761 (2013).
- 574 63. Y. Wei, R. M. Terns, M. P. Terns, Cas9 function and host genome sampling in Type II-A
575 CRISPR-Cas adaptation. *Genes Dev* **29**, 356-361 (2015).
- 576 64. E. Semenova *et al.*, Interference by clustered regularly interspaced short palindromic repeat
577 (CRISPR) RNA is governed by a seed sequence. *Proc Natl Acad Sci U S A* **108**, 10098-10103
578 (2011).
- 579 65. P. C. Fineran *et al.*, Degenerate target sites mediate rapid primed CRISPR adaptation. *Proc Natl*
580 *Acad Sci U S A* **111**, E1629-1638 (2014).
- 581 66. D. Paez-Espino *et al.*, Strong bias in the bacterial CRISPR elements that confer immunity to
582 phage. *Nat Commun* **4**, 1430 (2013).
- 583 67. C. Xue *et al.*, CRISPR interference and priming varies with individual spacer sequences. *Nucleic*
584 *Acids Res* **43**, 10831-10847 (2015).
- 585 68. K. A. Datsenko *et al.*, Molecular memory of prior infections activates the CRISPR/Cas adaptive
586 bacterial immunity system. *Nat Commun* **3**, 945 (2012).
- 587 69. D. C. Swarts, C. Mosterd, M. W. van Passel, S. J. Brouns, CRISPR interference directs strand
588 specific spacer acquisition. *PLoS One* **7**, e35888 (2012).

- 589 70. E. Savitskaya, E. Semenova, V. Dedkov, A. Metlitskaya, K. Severinov, High-throughput analysis
590 of type I-E CRISPR/Cas spacer acquisition in *E. coli*. *RNA Biol* **10**, 716-725 (2013).
- 591 71. A. G. Patterson, J. T. Chang, C. Taylor, P. C. Fineran, Regulation of the Type I-F CRISPR-Cas
592 system by CRP-cAMP and GalM controls spacer acquisition and interference. *Nucleic Acids Res*
593 **43**, 6038-6048 (2015).
- 594 72. K. Severinov, I. Ispolatov, E. Semenova, The Influence of Copy-Number of Targeted
595 Extrachromosomal Genetic Elements on the Outcome of CRISPR-Cas Defense. *Front Mol Biosci*
596 **3**, 45 (2016).
- 597 73. T. Künne *et al.*, Cas3-Derived Target DNA Degradation Fragments Fuel Primed CRISPR
598 Adaptation. *Mol Cell* **63**, 852-864 (2016).
- 599 74. S. Redding *et al.*, Surveillance and Processing of Foreign DNA by the *Escherichia coli* CRISPR-
600 Cas System. *Cell* **163**, 854-865 (2015).
- 601 75. T. R. Blosser *et al.*, Two distinct DNA binding modes guide dual roles of a CRISPR-Cas protein
602 complex. *Mol Cell* **58**, 60-70 (2015).
- 603 76. D. G. Sashital, B. Wiedenheft, J. A. Doudna, Mechanism of foreign DNA selection in a bacterial
604 adaptive immune system. *Mol Cell* **46**, 606-615 (2012).
- 605 77. M. F. Rollins, J. T. Schuman, K. Paulus, H. S. Bukhari, B. Wiedenheft, Mechanism of foreign
606 DNA recognition by a CRISPR RNA-guided surveillance complex from *Pseudomonas*
607 *aeruginosa*. *Nucleic Acids Res* **43**, 2216-2222 (2015).
- 608 78. R. P. Hayes *et al.*, Structural basis for promiscuous PAM recognition in type I-E Cascade from *E.*
609 *coli*. *Nature* **530**, 499-503 (2016).
- 610 79. P. B. van Erp *et al.*, Mechanism of CRISPR-RNA guided recognition of DNA targets in
611 *Escherichia coli*. *Nucleic Acids Res* **43**, 8381-8391 (2015).
- 612 80. M. Li, R. Wang, H. Xiang, *Haloarcula hispanica* CRISPR authenticates PAM of a target
613 sequence to prime discriminative adaptation. *Nucleic Acids Res* **42**, 7226-7235 (2014).
- 614 81. C. Xue, N. R. Whitis, D. G. Sashital, Conformational Control of Cascade Interference and
615 Priming Activities in CRISPR Immunity. *Mol Cell* **64**, 826-834 (2016).
- 616 82. T. Sinkunas *et al.*, Cas3 is a single-stranded DNA nuclease and ATP-dependent helicase in the
617 CRISPR/Cas immune system. *EMBO J* **30**, 1335-1342 (2011).
- 618 83. S. Mulepati, S. Bailey, In vitro reconstitution of an *Escherichia coli* RNA-guided immune system
619 reveals unidirectional, ATP-dependent degradation of DNA target. *J Biol Chem* **288**, 22184-
620 22192 (2013).
- 621 84. E. R. Westra *et al.*, CRISPR immunity relies on the consecutive binding and degradation of
622 negatively supercoiled invader DNA by Cascade and Cas3. *Mol Cell* **46**, 595-605 (2012).
- 623 85. Y. Huo *et al.*, Structures of CRISPR Cas3 offer mechanistic insights into Cascade-activated DNA
624 unwinding and degradation. *Nat Struct Mol Biol* **21**, 771-777 (2014).
- 625 86. C. Richter *et al.*, Priming in the Type I-F CRISPR-Cas system triggers strand-independent spacer
626 acquisition, bi-directionally from the primed protospacer. *Nucleic Acids Res* **42**, 8516-8526
627 (2014).
- 628 87. E. Semenova *et al.*, Highly efficient primed spacer acquisition from targets destroyed by the
629 *Escherichia coli* type I-E CRISPR-Cas interfering complex. *Proc Natl Acad Sci U S A* **113**, 7626-
630 7631 (2016).
- 631 88. M. Li, R. Wang, D. Zhao, H. Xiang, Adaptation of the *Haloarcula hispanica* CRISPR-Cas
632 system to a purified virus strictly requires a priming process. *Nucleic Acids Res* **42**, 2483-2492
633 (2014).
- 634 89. C. Rao *et al.*, Active and adaptive *Legionella* CRISPR-Cas reveals a recurrent challenge to the
635 pathogen. *Cell Microbiol* **18**, 1319-1338 (2016).
- 636 90. R. Heler *et al.*, Cas9 specifies functional viral targets during CRISPR-Cas adaptation. *Nature* **519**,
637 199-202 (2015).
- 638 91. T. R. Sampson, S. D. Saroj, A. C. Llewellyn, Y. L. Tzeng, D. S. Weiss, A CRISPR/Cas system
639 mediates bacterial innate immune evasion and virulence. *Nature* **497**, 254-257 (2013).

- 640 92. K. H. Nam, I. Kurinov, A. Ke, Crystal structure of clustered regularly interspaced short
641 palindromic repeats (CRISPR)-associated Csn2 protein revealed Ca²⁺-dependent double-
642 stranded DNA binding activity. *J Biol Chem* **286**, 30759-30768 (2011).
- 643 93. P. Ellinger *et al.*, The crystal structure of the CRISPR-associated protein Csn2 from
644 *Streptococcus agalactiae*. *J Struct Biol* **178**, 350-362 (2012).
- 645 94. Z. Arslan *et al.*, Double-strand DNA end-binding and sliding of the toroidal CRISPR-associated
646 protein Csn2. *Nucleic Acids Res* **41**, 6347-6359 (2013).
- 647 95. K. H. Lee *et al.*, Identification, structural, and biochemical characterization of a group of large
648 Csn2 proteins involved in CRISPR-mediated bacterial immunity. *Proteins* **80**, 2573-2582 (2012).
- 649 96. A. Plagens, B. Tjaden, A. Hagemann, L. Randau, R. Hensel, Characterization of the CRISPR/Cas
650 subtype I-A system of the hyperthermophilic crenarchaeon *Thermoproteus tenax*. *J Bacteriol* **194**,
651 2491-2500 (2012).
- 652 97. J. Zhang, T. Kasciukovic, M. F. White, The CRISPR associated protein Cas4 Is a 5' to 3' DNA
653 exonuclease with an iron-sulfur cluster. *PLoS One* **7**, e47232 (2012).
- 654 98. S. Lemak *et al.*, Toroidal structure and DNA cleavage by the CRISPR-associated [4Fe-4S] cluster
655 containing Cas4 nuclease SSO0001 from *Sulfolobus solfataricus*. *J Am Chem Soc* **135**, 17476-
656 17487 (2013).
- 657 99. C. R. Hale *et al.*, RNA-guided RNA cleavage by a CRISPR RNA-Cas protein complex. *Cell* **139**,
658 945-956 (2009).
- 659 100. G. W. Goldberg, W. Jiang, D. Bikard, L. A. Marraffini, Conditional tolerance of temperate
660 phages via transcription-dependent CRISPR-Cas targeting. *Nature* **514**, 633-637 (2014).
- 661 101. S. Silas *et al.*, Direct CRISPR spacer acquisition from RNA by a natural reverse transcriptase-
662 Cas1 fusion protein. *Science* **351**, aad4234 (2016).
- 663 102. G. E. Heussler, J. L. Miller, C. E. Price, A. J. Collins, G. A. O'Toole, Requirements for
664 *Pseudomonas aeruginosa* Type I-F CRISPR-Cas Adaptation Determined Using a Biofilm
665 Enrichment Assay. *J Bacteriol* **198**, 3080-3090 (2016).
- 666 103. M. Krupovic, K. S. Makarova, P. Forterre, D. Prangishvili, E. V. Koonin, Casposons: a new
667 superfamily of self-synthesizing DNA transposons at the origin of prokaryotic CRISPR-Cas
668 immunity. *BMC Biol* **12**, 36 (2014).
- 669 104. A. B. Hickman, F. Dyda, The casposon-encoded Cas1 protein from *Aciduliprofundum boonei* is a
670 DNA integrase that generates target site duplications. *Nucleic Acids Res* **43**, 10576-10587 (2015).
- 671 105. P. Beguin, N. Charpin, E. V. Koonin, P. Forterre, M. Krupovic, Casposon integration shows
672 strong target site preference and recapitulates protospacer integration by CRISPR-Cas systems.
673 *Nucleic Acids Res*, (2016).
- 674 106. E. V. Koonin, M. Krupovic, Evolution of adaptive immunity from transposable elements
675 combined with innate immune systems. *Nat Rev Genet* **16**, 184-192 (2015).
- 676 107. M. Krupovic, S. Shmakov, K. S. Makarova, P. Forterre, E. V. Koonin, Recent Mobility of
677 Casposons, Self-Synthesizing Transposons at the Origin of the CRISPR-Cas Immunity. *Genome*
678 *Biol Evol* **8**, 375-386 (2016).
- 679 108. O. S. Alkhnbashi *et al.*, Characterizing leader sequences of CRISPR loci. *Bioinformatics* **32**,
680 i576-i585 (2016).
- 681 109. A. G. Patterson *et al.*, Quorum Sensing Controls Adaptive Immunity through the Regulation of
682 Multiple CRISPR-Cas Systems. *Mol Cell*, (2016).
- 683 110. N. M. Høyland-Kroghsbo *et al.*, Quorum sensing controls the *Pseudomonas aeruginosa* CRISPR-
684 Cas adaptive immune system. *Proc Natl Acad Sci U S A*, (2016).
- 685 111. E. V. Koonin, F. Zhang, Coupling immunity and programmed cell suicide in prokaryotes: Life-
686 or-death choices. *Bioessays*, (2016).
- 687 112. R. Li *et al.*, Type I CRISPR-Cas targets endogenous genes and regulates virulence to evade
688 mammalian host immunity. *Cell Res* **26**, 1273-1287 (2016).
- 689 113. E. R. Westra, A. Buckling, P. C. Fineran, CRISPR-Cas systems: beyond adaptive immunity. *Nat*
690 *Rev Microbiol* **12**, 317-326 (2014).

- 691 114. C. Almendros, N. M. Guzman, J. Garcia-Martinez, F. J. Mojica, Anti-cas spacers in orphan
692 CRISPR4 arrays prevent uptake of active CRISPR-Cas I-F systems. *Nat Microbiol* **1**, 16081
693 (2016).
- 694 115. K. S. Makarova, V. Anantharaman, L. Aravind, E. V. Koonin, Live virus-free or die: coupling of
695 antiviral immunity and programmed suicide or dormancy in prokaryotes. *Biol Direct* **7**, 40
696 (2012).
- 697 116. M. E. Dupuis, M. Villion, A. H. Magadán, S. Moineau, CRISPR-Cas and restriction-modification
698 systems are compatible and increase phage resistance. *Nat Commun* **4**, 2087 (2013).
- 699 117. R. H. J. Staals, S. J. J. Brouns, in *CRISPR-Cas Systems: RNA-mediated Adaptive Immunity in*
700 *Bacteria and Archaea*, R. Barrangou, J. van der Oost, Eds. (Springer Berlin Heidelberg, Berlin,
701 Heidelberg, 2013), pp. 145-169.
- 702 118. J. Elmore, T. Deighan, J. Westpheling, R. M. Terns, M. P. Terns, DNA targeting by the type I-G
703 and type I-A CRISPR-Cas systems of *Pyrococcus furiosus*. *Nucleic Acids Res* **43**, 10353-10363
704 (2015).
- 705 119. J. Bondy-Denomy, A. Pawluk, K. L. Maxwell, A. R. Davidson, Bacteriophage genes that
706 inactivate the CRISPR/Cas bacterial immune system. *Nature* **493**, 429-432 (2013).
- 707 120. A. Pawluk *et al.*, Inactivation of CRISPR-Cas systems by anti-CRISPR proteins in diverse
708 bacterial species. *Nat Microbiol* **1**, 16085 (2016).
- 709 121. D. Vorontsova *et al.*, Foreign DNA acquisition by the I-F CRISPR-Cas system requires all
710 components of the interference machinery. *Nucleic Acids Res* **43**, 10848-10860 (2015).
- 711 122. S. D. Perli, C. H. Cui, T. K. Lu, Continuous genetic recording with self-targeting CRISPR-Cas in
712 human cells. *Science* **353**, (2016).

713

714 **Acknowledgments:** Work in the Fineran laboratory on CRISPR-Cas is supported by a
715 Rutherford Discovery Fellowship (PCF) from the Royal Society of New Zealand
716 (RSNZ), the Marsden Fund (RSNZ), the University of Otago and the Bio-protection
717 Research Centre (Tertiary Education Commission). The Brouns laboratory is funded by
718 an ERC starting grant (639707), an NWO VIDI grant (864.11.005), and FOM
719 projectruimte (15PR3188). We thank members of the Fineran and Brouns groups for
720 useful feedback on the manuscript.